EPAC1 activation offers significant promise in addressing critical conditions such as heart failure, type 2 diabetes, idiopathic pulmonary fibrosis (IPF), and vascular complications through its ability to modulate intracellular calcium handling, enhance endothelial barrier function, and regulate fibroblast activity. This evidence concerns the gene RAPGEF3 and idiopathic pulmonary fibrosis.